ITACONIX PLC (ITX) — Interim Results for the year ended 30 June 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ITACONIX PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, and I'd now like to hand you over to John Shaw, CEO. Good afternoon, sir. Good afternoon. John Sharp, CEO of ITACONIX, and welcome to our report on our interim results, for 2025. In terms of our highlights, it's a very important half year for us, for the long term development of ITACONIX into a large, highly profitable specialty ingredients company. Our h one highlights are really around our financial, results in a couple of different areas. We recorded record revenues, record gross profits, near neutral adjusted EBITDA, and we still have plenty of resources for additional growth. On our commercial progress side, we made a major step towards reaching profitability from both the revenue growth side and the revenue base we have in place for landing and expanding new customers. Finally, we're also setting up future growth with two major new initiatives that advance in the first half with both our sparks program, our biobasterisk program. Our path to be a large specialty ingredient company centers around the value and potential for itaconic acid. Itaconic acid is a natural molecule. It's a metabolite actually produced in our bodies in the natural world through biochemistry. Its value is...